Global Newswire by Notified: M&A

JULY 1, 2024

Protect Pharmaceutical Corp. Issues Corporate Update.

Pharmaceutical 49

Pharmaceutical Corporation 49

Global Newswire by Notified: M&A

JULY 28, 2023

Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3

Pharmaceutical 76

Pharmaceutical Shares 76

Cooley M&A

OCTOBER 19, 2022

Cooley’s M&A practice has been busy amid the typically slower summer wind down. Steaming through the third quarter, Cooley’s deal flow put us at the top of the Bloomberg, Mergermarket and Refinitiv Q3 M&A league tables. Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 64

M&A Pharmaceutical Acquisitions Valuation 64

Global Newswire by Notified: M&A

APRIL 23, 2024

a European distributor in the pharmaceutical and nutraceutical industry. ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U,

Pharmaceutical 52

Pharmaceutical IT Acquisitions Shares 52

Global Newswire by Notified: M&A

MARCH 21, 2024

March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. DEER PARK, Ill.,

Pharmaceutical 45

Pharmaceutical Acquisitions IT 45

Global Newswire by Notified: M&A

JUNE 12, 2024

Westford USA, June 12, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Active Pharmaceutical Ingredients Market will attain a value of USD 351.81 Furthermore, the changing consumer taste towards personalized and precision medicine is expected to drive the active pharmaceutical ingredient (API) market. Billion by 2031, with a CAGR of 5.9%

Pharmaceutical 40

Pharmaceutical 40

Global Newswire by Notified: M&A

DECEMBER 4, 2023

Rising demand for functional excipients and oral pharmaceutical medicines and increasing number of pharmaceuticals industries across the globe are key factors driving Pharmaceutical Excipients market revenue growth.

Pharmaceutical 40

Pharmaceutical 40

Global Newswire by Notified: M&A

MAY 10, 2024

Nika Pharmaceuticals, Inc. NIKA) acquired production building and land valued at $2,045,209 and signed a supply agreement for vial production line.

Pharmaceutical 40

Pharmaceutical 40

Global Newswire by Notified: M&A

MAY 10, 2024

Nika Pharmaceuticals, Inc. NIKA) acquired production building and land valued at $2,045,209 and signed a supply agreement for vial production line.

Pharmaceutical 40

Pharmaceutical 40

Global Newswire by Notified: M&A

JANUARY 4, 2024

Rising demand for pharmaceutical drugs and increasing drug Research & Development (R&D) activities are key factors driving Active Pharmaceutical Ingredients (API) market revenue growth Rising demand for pharmaceutical drugs and increasing drug Research & Development (R&D) activities are key factors driving Active Pharmaceutical Ingredients (..)

Pharmaceutical 40

Pharmaceutical 40

Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. Few would disagree the American healthcare sector faces a great many challenges in terms of accessibility, affordability, and quality of care.

Healthcare 52

Healthcare M&A Valuation Medical 52

Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. Few would disagree the American healthcare sector faces a great many challenges in terms of accessibility, affordability, and quality of care.

Healthcare 52

Healthcare M&A Valuation Medical 52

Devensoft

JUNE 19, 2023

Mergers and acquisitions (M&A) constitute intricate and frequently risky transactions with significant implications for stakeholders. That’s why companies need to approach M&A deals with a strategic mindset that minimizes risk and maximizes value.

M&A 52

M&A Mergers and Acquisitions Mergers Management 52

Global Newswire by Notified: M&A

MARCH 11, 2024

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. Nasdaq: CDT ) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation.

Pharmaceutical 45

Pharmaceutical Portfolio Acquisitions 45

Global Newswire by Notified: M&A

AUGUST 3, 2023

SkyQuest projects that the pharmaceutical contract development and manufacturing market will attain a value of USD 222.87 SkyQuest projects that the pharmaceutical contract development and manufacturing market will attain a value of USD 222.87 billion by 2030, with a CAGR of 6.9% over the forecast period (2023-2030).

Pharmaceutical 40

Pharmaceutical Manufacturing 40

Devensoft

AUGUST 22, 2023

Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Global Newswire by Notified: M&A

JANUARY 2, 2024

The global Pharmaceutical Packaging market size is expected to reach USD 249.41 Additionally, the rise in generic drug manufacturing, advancements in pharmaceutical technologies, and the push for sustainable and eco-friendly packaging options are also contributing factors fueling the market's growth.

Pharmaceutical 40

Pharmaceutical Healthcare Manufacturing 40

Global Newswire by Notified: M&A

JULY 2, 2024

July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. PALO ALTO, Calif., a Cayman Islands corporation and special purpose acquisition company (Nasdaq: DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0

Pharmaceutical 72

Pharmaceutical Acquisitions Capital Business 72

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 40

M&A Pharmaceutical Acquisitions Valuation 40

Global Newswire by Notified: M&A

JANUARY 31, 2024

The global Pharmaceutical Analytical Testing Outsourcing market size is expected to reach USD 15.09 The global Pharmaceutical Analytical Testing Outsourcing market size is expected to reach USD 15.09 billion by 2030 and exhibit a CAGR of 8.4% in the forecast period (2023−2030), according to Skyquest's latest research report.

Pharmaceutical 40

Pharmaceutical 40

Global Newswire by Notified: M&A

APRIL 15, 2024

Nika Pharmaceuticals, Inc. NKPH) announces the purchase of technologies for production of three generic drugs in tablet form and one dietary supplement.

Pharmaceutical 45

Pharmaceutical 45

Global Newswire by Notified: M&A

SEPTEMBER 22, 2023

22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., SAN DIEGO, Sept.

Pharmaceutical 40

Pharmaceutical Acquisitions Business 40

Global Newswire by Notified: M&A

MAY 6, 2024

("Lophos", or the "Company") (CSE:MESC) is pleased to announce that its wholly-owned subsidiary, Lophos Pharmaceuticals Corp.

Pharmaceutical 45

Pharmaceutical Sale Business IT 45

Global Newswire by Notified: M&A

MAY 1, 2024

SIPP Industries Announces Strategic Acquisition of Revenue Share in Calypso Pharmaceuticals to Bolster Position in Cannabis and Hemp Industries.

Pharmaceutical 40

Pharmaceutical Shares Acquisitions 40

Software Equity Group

JUNE 6, 2023

A key indicator is the increasing number of SaaS M&A transactions as companies seek to expand into new markets, consolidate current markets, provide end-to-end solutions, and take advantage of synergies. As a trusted partner in SaaS M&A, we are thrilled to have played a pivotal role in these significant deals.

M&A 52

M&A Mergers and Acquisitions Middle Market Acquisitions 52

Global Newswire by Notified: M&A

JULY 13, 2023

West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard ® (uridine triacetate) and Xuriden ® (uridine triacetate), from Wellstat Therapeutics.

Pharmaceutical 40

Pharmaceutical IT 40

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Global Newswire by Notified: M&A

AUGUST 4, 2023

SkyQuest projects that the pharmaceutical processing equipment market will attain a value of USD 15.71 The growth of the pharmaceutical processing equipment market can be attributed to several factors. SkyQuest projects that the pharmaceutical processing equipment market will attain a value of USD 15.71

Pharmaceutical 40

Pharmaceutical Manufacturing 40

Global Newswire by Notified: M&A

SEPTEMBER 29, 2023

29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc.

Pharmaceutical 45

Pharmaceutical Shares 45

Global Newswire by Notified: M&A

AUGUST 16, 2023

Rising use of drugs in the form of capsules and other forms of medication on a global scale is a key factor driving pharmaceutical packaging market revenue growth. Rising use of drugs in the form of capsules and other forms of medication on a global scale is a key factor driving pharmaceutical packaging market revenue growth.

Pharmaceutical 40

Pharmaceutical Medical 40

Global Newswire by Notified: M&A

JULY 18, 2023

TORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC Pink: POLXF) (the “Company” or “Polydex”) held a Special Meeting on July 14, 2023 relating to a Plan of Arrangement involving Polydex Pharmaceuticals Limited, Biospectra International Inc., and Biospectra Canada Inc.,

Pharmaceutical 40

Pharmaceutical Business Shares 40

Global Newswire by Notified: M&A

FEBRUARY 16, 2024

The rising demand for succinic Acid (SA) can be attributed to its expanding utility in pharmaceutical manufacturing and its pivotal role in building and infrastructure development operations in the global succinic acid market. SkyQuest projects that the global succinic acid market will attain a value of USD 562.57

Utilities 40

Utilities Pharmaceutical Manufacturing IT 40

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Global Newswire by Notified: M&A

JUNE 27, 2023

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. together with its affiliates (collectively, "NexPoint").

Pharmaceutical 40

Pharmaceutical Asset Management Management IT 40

Global Newswire by Notified: M&A

MARCH 27, 2024

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc.

Pharmaceutical 40

Pharmaceutical Equities Acquisitions IT 40

Global Newswire by Notified: M&A

AUGUST 3, 2023

03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. BOSTON, Aug. NYSE: HTGC) (“Hercules”).

Pharmaceutical 40

Pharmaceutical Capital IT 40